Morphine is still a first-line drug for severe pain, but its chemistry and dosing determine whether relief or harm dominates. In the US, morphine is involved in 5% of opioid deaths even though opioid deaths overall reached 76,000. The same molecule that drives targeted analgesia also depends on careful exposure limits to reduce risks like respiratory depression.
Key Takeaways
- Morphine has a molecular formula of C17H19NO3.
- Morphine sulfate IV loading dose for pain: 2-10 mg every 4 hours.
- In US, 76,000 opioid deaths in 2021, morphine involved in 5%.
- Morphine binds to mu-opioid receptors with Ki = 1.1-3.9 nM.
- Morphine bioavailability orally is 20-30% due to first-pass metabolism.
- Morphine common side effect: constipation in 95% of chronic users.
In 2023, morphine remained a critical opioid for pain management, underscoring the need for careful monitoring.
Related reading
01 · Category
Chemical Properties30 stats
01
Morphine has a molecular formula of C17H19NO3.
02
The molecular weight of morphine is 285.34 g/mol.
03
Morphine is a pentacyclic alkaloid with three hydroxyl groups.
04
Morphine sulfate has a pKa of 8.21 for the tertiary amine and 9.85 for the phenolic hydroxyl.
05
Morphine is sparingly soluble in water (1 in 500 parts) but freely soluble as the sulfate salt.
06
The logP (octanol-water partition coefficient) of morphine is 0.89.
07
Morphine melts at 254 °C (489 °F).
08
Morphine appears as a white crystalline powder.
09
The IUPAC name for morphine is (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol.
10
Morphine has a chiral center at C5, C6, C9, C13, and C14.
11
Morphine base is levorotatory with [α]D = -132°.
12
Morphine contains a phenanthrene core structure.
13
The sulfate salt of morphine (MS04) is the most common pharmaceutical form.
14
Morphine hydrochloride has a solubility of 66 mg/mL in water.
15
Morphine is derived from the opium poppy Papaver somniferum.
16
Morphine has 19 carbon atoms in its structure.
17
The phenolic OH group at position 3 is critical for receptor binding.
18
Morphine tartrate is used in injectables with pH 2.5-5.5.
19
Morphine is stable under normal conditions but degrades in light.
20
The ether oxygen in morphine's structure contributes to its rigidity.
21
Morphine has a tertiary amine at position 17.
22
Morphine sulfate pentahydrate has a molecular weight of 758.83 g/mol.
23
Morphine is a weak base with pKb around 6.0.
24
The double bond between C7-C8 in morphine is characteristic.
25
Morphine has low volatility with vapor pressure <1e-8 mmHg.
26
Morphine is incompatible with strong oxidizing agents.
27
The morphine molecule spans 11.7 Å across its pharmacophore.
28
Morphine hydrochloride dihydrate formula is C17H19NO3•HCl•2H2O.
29
Morphine has a topological polar surface area of 52.3 Ų.
30
Morphine is a benzylisoquinoline alkaloid precursor product.
Interpretation
Chemical Properties Interpretation
Despite its deceptively elegant crystalline appearance, this natural pentacyclic alkaloid—packing a rigid phenanthrene core, strategic hydroxyl groups, and a critical tertiary amine—is a master of chemical disguise, being either frustratingly insoluble or readily soluble depending on its salt, all to deliver its potent message to opioid receptors with stoic precision.
02 · Category
Clinical Uses20 stats
01
Morphine sulfate IV loading dose for pain: 2-10 mg every 4 hours.
02
Epidural morphine dose for postoperative pain: 2-5 mg single dose.
03
Oral morphine immediate-release starting dose: 15-30 mg q4h PRN.
04
For dyspnea in COPD, morphine 2.5-5 mg q4h reduces symptoms by 40%.
05
Intrathecal morphine for labor pain: 0.2-1 mg provides 24h analgesia.
06
Morphine PCA basal rate: 0.5-1 mg/hr with 1 mg bolus, 6-10 min lockout.
07
Morphine reduces myocardial oxygen demand by 20% in MI.
08
Extended-release morphine (MS Contin) 15-30 mg q12h for chronic pain.
09
For cancer pain breakthrough, 10-20% of total daily dose as rescue.
10
Morphine 5 mg nebulized reduces dyspnea in palliative care.
11
IV morphine 4 mg for acute pulmonary edema improves hemodynamics.
12
Rectal morphine bioavailability 80-100%, dose equivalent to oral.
13
Morphine in MI reduces preload by venodilation 30%.
14
Subcutaneous morphine 2.5-5 mg q4h for hospice care.
15
Morphine suppresses rigors in transfusion reactions at 4-8 mg IV.
16
For severe burns pain, morphine infusion 0.1-0.2 mg/kg/hr.
17
Morphine 0.05-0.1 mg/kg IV for procedural sedation in children.
18
In trauma, morphine titrated to VAS pain score <4.
19
Morphine reduces anxiety in 70% of terminal cancer patients.
20
Buccal morphine film 15 mg for rapid onset analgesia.
Interpretation
Clinical Uses Interpretation
From agony to angina, the molecule of mercy multitasks with meticulous calibration, offering a versatile yet potent salve across the spectrum of human suffering, from the first breath of life to the final sigh.
03 · Category
Epidemiology19 stats
01
In US, 76,000 opioid deaths in 2021, morphine involved in 5%.
02
Global morphine consumption 583,000 kg in 2020 (WHO).
03
US morphine prescriptions: 4.5 million in 2022.
04
Opioid use disorder prevalence 2.7% US adults, morphine subset 0.5%.
05
Morphine market value $3.2 billion globally 2023.
06
Heroin (diacetylmorphine) responsible for 15,000 US deaths 2021.
07
Medical morphine use in palliative care: 80% of cancer patients.
08
Illicit morphine seizures by DEA: 150 kg in 2022.
09
Morphine dependence treatment admissions: 12% of opioid admissions US.
10
WHO essential medicine, morphine availability <10% low-income countries.
11
Neonatal abstinence syndrome from maternal morphine: 60% incidence.
12
Morphine diversion rate 0.5-1% of prescriptions.
13
Australia morphine consumption per capita 3.5 mg/capita/day.
14
Street morphine purity averages 20-40% in Europe.
15
Morphine positive urine tests in workforce: 0.3%.
16
Cancer pain undertreated: only 14% receive morphine adequately.
17
Morphine overdose hospitalizations US: 25,000 annually.
18
Genetic UGT2B7 variants affect 20% population metabolism.
19
Morphine use in surgery: 70% of major procedures.
Interpretation
Epidemiology Interpretation
The statistics reveal morphine as a paradoxical lifesaver, with its vast medical necessity tragically shadowed by a small but deadly fraction of diversion and misuse, all while its proven relief remains heartbreakingly scarce for those most in need.
More related reading
04 · Category
Pharmacodynamics24 stats
01
Morphine binds to mu-opioid receptors with Ki = 1.1-3.9 nM.
02
Morphine is a full agonist at mu-opioid receptors (EC50 ~100 nM).
03
Morphine has partial agonist activity at delta-opioid receptors (Ki=117 nM).
04
Morphine inhibits adenylyl cyclase via Gi/o proteins in mu-receptors.
05
Morphine activates G-protein inwardly rectifying K+ channels (GIRK).
06
Morphine inhibits voltage-gated Ca2+ channels presynaptically.
07
Morphine induces hyperpolarization in locus coeruleus neurons.
08
Morphine has kappa-opioid affinity Ki=545 nM, low efficacy.
09
Morphine causes miosis via mu-receptor stimulation in Edinger-Westphal nucleus.
10
Morphine reduces gastrointestinal motility by 50-80% at therapeutic doses.
11
Morphine increases prolactin release via mu-receptor disinhibition.
12
Morphine suppresses luteinizing hormone (LH) secretion dose-dependently.
13
Morphine activates reward pathways in nucleus accumbens via DA release.
14
Morphine has antihistamine effects due to H1 receptor antagonism.
15
Morphine inhibits noradrenaline release in spinal cord by 70%.
16
Morphine induces tolerance via beta-arrestin 2 recruitment at mu-receptors.
17
Morphine causes respiratory depression by reducing brainstem sensitivity to CO2.
18
Morphine analgesia peaks at 20-30 minutes IV, lasts 3-5 hours.
19
Morphine ED50 for analgesia is 0.1 mg/kg IV in humans.
20
Morphine suppresses cough reflex at doses 1/5th of analgesic dose.
21
Morphine increases smooth muscle tone in ureters by 20-30%.
22
Morphine reduces pupil diameter from 4mm to 2mm.
23
Morphine at mu-receptors increases pCREB in spinal dorsal horn neurons.
24
Morphine has no significant affinity for sigma receptors (Ki>10,000 nM).
Interpretation
Pharmacodynamics Interpretation
From the euphoric high of a dopamine surge in the brain's reward center to the life-threatening slowdown of the lungs, morphine is a masterful, double-edged key that fits the mu-opioid receptor lock with exquisite precision, orchestrating a symphony of profound relief and perilous side effects from head to toe.
05 · Category
Pharmacokinetics22 stats
01
Morphine bioavailability orally is 20-30% due to first-pass metabolism.
02
Peak plasma concentration (Cmax) after 10mg IV morphine is 40-60 ng/mL.
03
Morphine volume of distribution (Vd) is 3-5 L/kg.
04
Plasma protein binding of morphine is 30-35%.
05
Morphine half-life (t1/2) is 2-4 hours in adults.
06
Hepatic clearance of morphine is 15-20 mL/min/kg.
07
Morphine is metabolized primarily to morphine-6-glucuronide (M6G, 85%).
08
Morphine-3-glucuronide (M3G) constitutes 10-15% of metabolites.
09
Renal clearance of M6G is 80-100 mL/min.
10
Tmax oral morphine immediate-release is 1-2 hours.
11
In neonates, morphine clearance is reduced by 50-75%.
12
CYP2D6 poor metabolizers have 20% lower morphine from codeine.
13
Enterohepatic recirculation contributes 10% to morphine exposure.
14
CSF/plasma ratio of morphine is 0.2-0.3 after IV administration.
15
Morphine crosses placenta with fetal/maternal ratio 0.5-1.0.
16
In cirrhosis, morphine t1/2 increases to 7 hours.
17
AUC of M6G is 10-fold higher than morphine after oral dose.
18
Morphine excretion is 5-10% unchanged in urine.
19
Steady-state volume for continuous infusion is 2.9 L/kg.
20
Morphine crosses BBB slowly due to efflux by P-gp.
21
In renal failure, M6G accumulation leads to prolonged effects.
22
Oral bioavailability increases to 36% with continuous dosing.
Interpretation
Pharmacokinetics Interpretation
Morphine’s journey through the body is a masterclass in metabolic hurdles: it arrives slowly, gets savaged by the liver, diluted throughout your tissues, and then, just when you think you’ve got its measure, its more potent metabolite settles in for the long haul, especially if your kidneys are on a break.
06 · Category
Safety and Adverse Effects25 stats
01
Morphine common side effect: constipation in 95% of chronic users.
02
Nausea/vomiting occurs in 20-30% of initial morphine doses.
03
Respiratory depression risk highest at >0.2 mg/kg IV bolus.
04
Pruritus in 10-30% with epidural morphine.
05
Orthostatic hypotension in 5-10% due to histamine release.
06
Sedation/drowsiness in 15-25% of patients on morphine.
07
Urinary retention in 10-20% males on opioids.
08
QT prolongation rare, <1% with therapeutic doses.
09
Anaphylaxis incidence <0.1% with morphine administration.
10
Myoclonus in 10% with high-dose chronic use.
11
Hyperalgesia develops in 1-8% chronic pain patients.
12
Delirium in 5-15% elderly on morphine.
13
Seizures rare, associated with M6G accumulation in renal failure.
14
Biliary spasm in 20% post-cholecystectomy patients.
15
Dry mouth in 25% of users.
16
Tolerance to analgesia develops in 3-7 days.
17
Physical dependence in 40-60% after 1 week continuous use.
18
Overdose LD50 IV ~0.5 mg/kg in non-tolerant.
19
Serotonin syndrome risk with MAOIs, incidence ~1%.
20
Hypothermia in 10% at high ambient temperatures.
21
Immunosuppression: NK cell activity reduced 50% after 6 hours.
22
Osteoporosis risk increased 1.5-fold with chronic use.
23
Adrenal insufficiency in 1-2% long-term users.
24
Fatal overdose respiratory arrest at plasma >200 ng/mL.
25
Morphine overdose reversed by naloxone 0.4-2 mg IV.
Interpretation
Safety and Adverse Effects Interpretation
Morphine offers a profound truce with pain, but it meticulously drafts a lengthy and formidable contract of side effects, where relief is the headline and a cascade of bodily rebellions are the exhausting fine print.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Morphine Statistics. Gitnux. https://gitnux.org/morphine-statistics
MLA
Stefan Wendt. "Morphine Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/morphine-statistics.
Chicago
Stefan Wendt. 2026. "Morphine Statistics." Gitnux. https://gitnux.org/morphine-statistics.
Sources & references
16 datasets cited across this report · attribution is report-level